Jury still out on Sarepta’s next generation
The group’s lead next-gen exon skipper beats a low bar set by Exondys, but adverse events loom large.
Dangling PD-1s emerge strong from three-day grilling
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
